Mavacamten, a drug initially developed to treat hypertrophic cardiomyopathy, has shown signs of reducing heart stress in ...

肾功能不全在心力衰竭患者中很常见，且与不良预后相关。然而，在这一人群中，心脏结构和功能与肾功能下降的关系尚不清楚。近日，Circulation: Heart ...

Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.

STAT asked 11 experts, including the FDA commissioner, why the world's wealthiest nation is doing so poorly on cardiovascular ...

Global Commercial Launch Preparations Underway for First Potential Approval Towards Building Specialty Cardiovascular Franchise Company Recently Launched Unbranded Disease Awareness Campaign “HCM ...

Cardiovascular disease, sometimes abbreviated as CVD, is the leading cause of death worldwide. It’s a catchall term for heart ...

USA: A recent study from the EMBARK-HFpEF trial has revealed promising results regarding using mavacamten, a cardiac myosin ...

Among the benefits of semaglutide, the GLP-1 receptor agonist may protect against heart failure events in patients with type 2 diabetes and CKD.

Oct. 4, 2024 — Researchers identified a lipid that is involved in regulating cardiac ion channels, providing insights into possible mechanisms of cardiac arrhythmias in heart failure and a ...

Javed Butler, MD, MPH, MBA, discusses the DAPA ECHO trial data presented at European Society of Cardiology Congress 2024, examining the effects of dapagliflozin on myocardial performance in patients ...

Comorbid diabetes was linked to worse functional and mortality outcomes, including maximum oxygen consumption, among patients with heart failure.